Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) EBT (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBT for 4 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 137.08% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$53.0 million through Dec 2025, up 13.11% year-over-year, with the annual reading at -$53.0 million for FY2025, 13.11% up from the prior year.
  • EBT for Q4 2025 was $6.0 million at Orchestra BioMed Holdings, up from -$20.8 million in the prior quarter.
  • The five-year high for EBT was $6.0 million in Q4 2025, with the low at -$20.8 million in Q3 2025.
  • Average EBT over 4 years is -$12.3 million, with a median of -$13.2 million recorded in 2023.
  • The sharpest move saw EBT crashed 125.14% in 2023, then surged 137.08% in 2025.
  • Over 4 years, EBT stood at -$9.8 million in 2022, then decreased by 15.72% to -$11.4 million in 2023, then plummeted by 42.05% to -$16.2 million in 2024, then soared by 137.08% to $6.0 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $6.0 million, -$20.8 million, and -$19.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.